Zydus Lifesciences gets FDA tentative approval for Gabapentin Tablets
Zydus Lifesciences said that its subsidiary Zydus Pharmaceuticals (USA) has secured tentative approval for once-daily Gabapentin Tablets, 300 mg and 600 mg from the US Food and Drug Administration (FDA). The approved product is the generic of Gralise Tablets, which are used for managing postherpetic neuralgia (PHN). As per IQVIA MAT December 2022, the annual […]